Response Biomedical Receives FDA 510(k) Clearance of Rapid Influenza A+B Test
go back to news archives Response Biomedical Corporation has received FDA 510(k) clearance to market a rapid Influenza A+B test (Flu A+B test) and a new version of the RAMP® Reader, the RAMP® 200. The test manufactured by Response Biomedical runs on the new RAMP® 200 Reader and will be marketed and sold worldwide exclusively by 3M Health Care as the 3M™ Rapid Detection Flu A+B Test. It is a qualitative immunochromatographic assay indicated for use as an in vitro diagnostic product with the 3M™ Rapid Detection Reader (manufactured by Response) to identify the presence of Flu A and Flu B nucleoprotein antigen in nasopharyngeal swab, nasopharyngeal aspirate, nasal wash/aspirate specimens. Measurement of Flu A and Flu B aids in the rapid differential diagnosis of influenza viral infections through use of this test. 3M Health Care anticipates launching prior to the 2008-09 flu season in certain markets around the world. |
NOTE: This item is from our 'historic' database and
may contain information which is not up to date.
Source : Response Biomedical Corp. View Company Information
Posted on April 22, 2008
LATEST MICROBIOLOGY NEWS
MICROBIOLOGY EVENTS
-
USP Chapter <86> and the Move to Recombinant Methods
29 Apr 2025 -
2025 Novogene Sequencing Symposium
8 May 2025 -
Explore the Future of Sterility Testing with Rapid Micro Biosystems®
14 May 2025 -
Understanding USP <73> to Accelerate Sterility Testing for Short-Life Products
14 May 2025 -
British Society For Microbial Technology 40th Anniversary Microbiology Conference
15 May 2025 -
How Is VIDAS® KUBE™ Transforming Food Pathogen Detection?
19 May 2025 -
Sampling and Microbial Testing of Water and Data Trending
20 May 2025 -
European Microbiology Conference and Workshop 2025
20 May 2025 -
Future Labs Live 2025
27 May 2025 -
2025 Endotoxin Testing Summit
10 Jun 2025